{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,15]],"date-time":"2026-11-15T20:59:06Z","timestamp":1794776346792,"version":"4.9.1"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,12,28]],"date-time":"2022-12-28T00:00:00Z","timestamp":1672185600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,12,28]],"date-time":"2022-12-28T00:00:00Z","timestamp":1672185600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100009592","name":"Beijing Municipal Science & Technology Commission","doi-asserted-by":"crossref","award":["Z181100001718136"],"award-info":[{"award-number":["Z181100001718136"]}],"id":[{"id":"10.13039\/501100009592","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Beijing Hope Run Special Fund of Cancer Foundation of China","award":["LC2018A24"],"award-info":[{"award-number":["LC2018A24"]}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82073352"],"award-info":[{"award-number":["82073352"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Radiat Oncol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>The safety of an MRI simulation-guided boost after short-course preoperative radiotherapy (SCPRT) for unresectable rectal cancer is assessed with a planned interim analysis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and materials<\/jats:title>\n                    <jats:p>Patients diagnosed with clinical stage T3-4 or regional lymph node-positive disease with positive mesorectal fascia or T4b disease evaluated by pelvic MRI were randomly assigned to the SCPRT-boost group (25\u00a0Gy in 5 fractions plus 4\u00a0Gy delivered to the gross tumor volume, followed by four cycles of chemotherapy) or preoperative chemoradiotherapy group (50\u00a0Gy in 25 fractions with concurrent chemotherapy). Then, patients received total mesorectal excision surgery after preoperative treatment. The primary endpoint was the R0 resection rate. The interim analysis was performed when 42 patients completed their assigned treatments.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>From October 2018 to November 2019, a total of 43 patients were enrolled, and 42 patients were included in the interim analysis. During preoperative therapy, grade 3 or above toxicities were observed in 10\/21 (47.6%) patients in the experimental group, and 4\/21 (19.0%) patients in the control group. A total of 17 (81.0%) and 13 (61.9%) patients in the experimental group and control group underwent surgery, respectively. Overall, 65.1% of the patients achieved R0 resection in the intention-to-treat analysis. Surgery-related adverse complications were observed in 2 patients (11.8%) in the experimental group and 1 patient (7.7%) in the control group.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Our results show that the toxicity of an MRI simulation-guided boost after SCPRT for unresectable rectal cancer is acceptable. Thus, this clinical trial will be continued as planned.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13014-022-02182-4","type":"journal-article","created":{"date-parts":[[2022,12,28]],"date-time":"2022-12-28T03:03:14Z","timestamp":1672196594000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["The safety of an MRI simulation-guided boost after short-course preoperative radiotherapy for unresectable rectal cancer (SUNRISE): interim analysis of a randomized phase II trial"],"prefix":"10.1186","volume":"17","author":[{"given":"Wen-Yang","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin-Ming","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ning","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan-Hong","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yihebali","family":"Chi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong-Kun","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong-Jian","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong-Da","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ning-Ning","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shu-Nan","family":"Qi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shu-Lian","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong-Wen","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue-Ping","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ye-Xiong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zheng","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hai-Tao","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian-Wei","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xi-Shan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hai-Zeng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,12,28]]},"reference":[{"issue":"3","key":"2182_CR1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209\u201349.","journal-title":"CA Cancer J Clin"},{"issue":"3","key":"2182_CR2","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1007\/BF02104452","volume":"16","author":"RM Devine","year":"1992","unstructured":"Devine RM, Dozois RR. Surgical management of locally advanced adenocarcinoma of the rectum. World J Surg. 1992;16(3):486\u20139.","journal-title":"World J Surg"},{"issue":"22","key":"2182_CR3","doi-asserted-by":"publisher","first-page":"3687","DOI":"10.1200\/JCO.2007.15.3858","volume":"26","author":"M Braendengen","year":"2008","unstructured":"Braendengen M, Tveit KM, Berglund A, et al. Randomized phase III study comparing preoperative radiotherapy with chemoradiotherapy in nonresectable rectal cancer. J Clin Oncol. 2008;26(22):3687\u201394.","journal-title":"J Clin Oncol"},{"issue":"suppl_4","key":"2182_CR4","doi-asserted-by":"publisher","first-page":"iv22","DOI":"10.1093\/annonc\/mdx224","volume":"28","author":"R Glynne-Jones","year":"2017","unstructured":"Glynne-Jones R, Wyrwicz L, Tiret E, et al. Rectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017;28(suppl_4):iv22\u201340.","journal-title":"Ann Oncol"},{"issue":"5","key":"2182_CR5","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1093\/annonc\/mdw062","volume":"27","author":"K Bujko","year":"2016","unstructured":"Bujko K, Wyrwicz L, Rutkowski A, et al. Long-course oxaliplatin-based preoperative chemoradiation versus 5 \u00d7 5 Gy and consolidation chemotherapy for cT4 or fixed cT3 rectal cancer: results of a randomized phase III study. Ann Oncol. 2016;27(5):834\u201342.","journal-title":"Ann Oncol"},{"issue":"7","key":"2182_CR6","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1007\/s00384-012-1630-4","volume":"28","author":"R Engineer","year":"2013","unstructured":"Engineer R, Mohandas KM, Shukla PJ, et al. Escalated radiation dose alone vs. concurrent chemoradiation for locally advanced and unresectable rectal cancers: results from phase II randomized study. Int J Colorectal Dis. 2013;28(7):959\u201366.","journal-title":"Int J Colorectal Dis"},{"issue":"1","key":"2182_CR7","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/S1470-2045(20)30555-6","volume":"22","author":"RR Bahadoer","year":"2021","unstructured":"Bahadoer RR, Dijkstra EA, van Etten B, et al. Short-course radiotherapy followed by chemotherapy before total mesorectal excision (TME) versus preoperative chemoradiotherapy, TME, and optional adjuvant chemotherapy in locally advanced rectal cancer (RAPIDO): a randomised, open-label, phase 3 trial. Lancet Oncol. 2021;22(1):29\u201342.","journal-title":"Lancet Oncol"},{"key":"2182_CR8","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1016\/j.radonc.2019.03.016","volume":"135","author":"J Erlandsson","year":"2019","unstructured":"Erlandsson J, L\u00f6rinc E, Ahlberg M, et al. Tumour regression after radiotherapy for rectal cancer\u2013results from the randomised Stockholm III trial. Radiother Oncol. 2019;135:178\u201386.","journal-title":"Radiother Oncol"},{"issue":"1","key":"2182_CR9","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.ijrobp.2012.05.017","volume":"85","author":"AL Appelt","year":"2013","unstructured":"Appelt AL, Pl\u00f8en J, Vogelius IR, Bentzen SM, Jakobsen A. Radiation dose-response model for locally advanced rectal cancer after preoperative chemoradiation therapy. Int J Radiat Oncol Biol Phys. 2013;85(1):74\u201380.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"4","key":"2182_CR10","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1016\/j.ijrobp.2020.06.013","volume":"108","author":"AM Couwenberg","year":"2020","unstructured":"Couwenberg AM, Burbach JPM, Berbee M, et al. Efficacy of dose-escalated chemoradiation on complete tumor response in patients with locally advanced rectal cancer (RECTAL-BOOST): a phase 2 randomized controlled trial. Int J Radiat Oncol Biol Phys. 2020;108(4):1008\u201318.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"15","key":"2182_CR11","doi-asserted-by":"publisher","first-page":"1681","DOI":"10.1200\/JCO.21.01667","volume":"40","author":"J Jin","year":"2022","unstructured":"Jin J, Tang Y, Hu C, et al. Multicenter, randomized, phase III trial of short-term radiotherapy plus chemotherapy versus long-term chemoradiotherapy in locally advanced rectal cancer (STELLAR). J Clin Oncol. 2022;40(15):1681\u201392.","journal-title":"J Clin Oncol."},{"issue":"991","key":"2182_CR12","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1259\/bjr\/31372149","volume":"83","author":"JF Fowler","year":"2010","unstructured":"Fowler JF. 21 years of biologically effective dose. Br J Radiol. 2010;83(991):554\u201368.","journal-title":"Br J Radiol"},{"key":"2182_CR13","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1002\/pro6.1141","volume":"6","author":"S Liu","year":"2022","unstructured":"Liu S, Jin J. Radiotherapy guidelines for rectal cancer in China 2020 edition. Precis Radiat Oncol. 2022;6:4\u201331.","journal-title":"Precis Radiat Oncol"},{"issue":"3","key":"2182_CR14","doi-asserted-by":"publisher","first-page":"e353","DOI":"10.1016\/j.ijrobp.2012.01.023","volume":"83","author":"HA Gay","year":"2012","unstructured":"Gay HA, Barthold HJ, O\u2019Meara E, et al. Pelvic normal tissue contouring guidelines for radiation therapy: a radiation therapy oncology group consensus panel atlas. Int J Radiat Oncol Biol Phys. 2012;83(3):e353-362.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"2182_CR15","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.ijrobp.2021.09.027","volume":"112","author":"R Timmerman","year":"2022","unstructured":"Timmerman R. A Story of Hypofractionation and the Table on the Wall. Int J Radiat Oncol Biol Phys. 2022;112(1):4\u201321.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2182_CR16","doi-asserted-by":"crossref","unstructured":"Pavy JJ, Denekamp J, Letschert J, et al. EORTC Late Effects Working Group. Late Effects toxicity scoring: the SOMA scale. Int J Radiat Oncol Biol Phys. 1995;31(5):1043-1047.","DOI":"10.1016\/0360-3016(95)00059-8"},{"issue":"1","key":"2182_CR17","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1007\/s003840050072","volume":"12","author":"O Dworak","year":"1997","unstructured":"Dworak O, Keilholz L, Hoffmann A. Pathological features of rectal cancer after preoperative radiochemotherapy. Int J Colorectal Dis. 1997;12(1):19\u201323.","journal-title":"Int J Colorectal Dis"},{"issue":"9290","key":"2182_CR18","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.1016\/S0140-6736(01)06409-1","volume":"358","author":"Colorectal Cancer Collaborative Group","year":"2001","unstructured":"Colorectal Cancer Collaborative Group. Adjuvant radiotherapy for rectal cancer: a systematic overview of 8,507 patients from 22 randomised trials. Lancet. 2001;358(9290):1291\u2013304.","journal-title":"Lancet."},{"issue":"4","key":"2182_CR19","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1097\/00000658-200204000-00001","volume":"235","author":"KF Birbeck","year":"2002","unstructured":"Birbeck KF, Macklin CP, Tiffin NJ, et al. Rates of circumferential resection margin involvement vary between surgeons and predict outcomes in rectal cancer surgery. Ann Surg. 2002;235(4):449\u201357.","journal-title":"Ann Surg"},{"issue":"12","key":"2182_CR20","doi-asserted-by":"publisher","first-page":"1859","DOI":"10.1016\/j.ejso.2016.08.001","volume":"42","author":"K Wisniowska","year":"2016","unstructured":"Wisniowska K, Nasierowska-Guttmejer A, Polkowski W, et al. Does the addition of oxaliplatin to preoperative chemoradiation benefit cT4 or fixed cT3 rectal cancer treatment? A subgroup analysis from a prospective study. Eur J Surg Oncol. 2016;42(12):1859\u201365.","journal-title":"Eur J Surg Oncol"},{"issue":"1","key":"2182_CR21","doi-asserted-by":"publisher","first-page":"S127","DOI":"10.1016\/j.ijrobp.2015.07.303","volume":"93","author":"HTY Ren","year":"2015","unstructured":"Ren H, Tang Y, Jin J, et al. Preoperative chemoradiation with a simultaneous integrated boost compared to regular preoperative chemoradiation for locally advanced rectal cancer: interim analysis of a randomized phase 2 trial (NCT02195141). Int J Radiat Oncol Biol Phys. 2015;93(1):S127.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"4","key":"2182_CR22","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1016\/j.ijrobp.2012.01.045","volume":"84","author":"JH Lee","year":"2012","unstructured":"Lee JH, Kim DY, Nam TK, et al. Long-term follow-up of preoperative pelvic radiation therapy and concomitant boost irradiation in locally advanced rectal cancer patients: a multi-institutional phase II study (KROG 04\u201301). Int J Radiat Oncol Biol Phys. 2012;84(4):955\u201361.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"7572","key":"2182_CR23","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1136\/bmj.38937.646400.55","volume":"333","author":"Group MS","year":"2006","unstructured":"Group MS. Diagnostic accuracy of preoperative magnetic resonance imaging in predicting curative resection of rectal cancer: prospective observational study. BMJ Clin Res Ed. 2006;333(7572):779.","journal-title":"BMJ Clin Res Ed."},{"key":"2182_CR24","doi-asserted-by":"crossref","unstructured":"Conroy T, Bosset JF, Etienne PL, et al. Neoadjuvant chemotherapy with FOLFIRINOX and preoperative chemoradiotherapy for patients with locally advanced rectal cancer (UNICANCER-PRODIGE 23): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2021;22(5):702\u201315.","DOI":"10.1016\/S1470-2045(21)00079-6"},{"key":"2182_CR25","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.radonc.2020.03.011","volume":"147","author":"MJM van der Valk","year":"2020","unstructured":"van der Valk MJM, Marijnen CAM, van Etten B, et al. Compliance and tolerability of short-course radiotherapy followed by preoperative chemotherapy and surgery for high-risk rectal cancer: results of the international randomized RAPIDO-trial. Radiother Oncol. 2020;147:75\u201383.","journal-title":"Radiother Oncol"},{"key":"2182_CR26","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.ctro.2020.11.016","volume":"26","author":"P Bonomo","year":"2021","unstructured":"Bonomo P, Lo Russo M, Nachbar M, et al. 1.5 T MR-linac planning study to compare two different strategies of rectal boost irradiation. Clin Transl Radiat Oncol. 2021;26:86\u201391.","journal-title":"Clin Transl Radiat Oncol"},{"issue":"1","key":"2182_CR27","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1186\/s12885-021-09158-9","volume":"22","author":"G Chiloiro","year":"2022","unstructured":"Chiloiro G, Cusumano D, Boldrini L, et al. THUNDER 2: THeragnostic Utilities for Neoplastic DisEases of the Rectum by MRI guided radiotherapy. BMC Cancer. 2022;22(1):67.","journal-title":"BMC Cancer"}],"container-title":["Radiation Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13014-022-02182-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13014-022-02182-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13014-022-02182-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,28]],"date-time":"2022-12-28T03:04:25Z","timestamp":1672196665000},"score":1,"resource":{"primary":{"URL":"https:\/\/ro-journal.biomedcentral.com\/articles\/10.1186\/s13014-022-02182-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,28]]},"references-count":27,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["2182"],"URL":"https:\/\/doi.org\/10.1186\/s13014-022-02182-4","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-2151740\/v1","asserted-by":"object"}]},"ISSN":["1748-717X"],"issn-type":[{"value":"1748-717X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,28]]},"assertion":[{"value":"10 October 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 December 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 December 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study met the rapid review conditions and institutional review board approval was obtained for this trial from the ethical committee of the Chinese Academy of Medical Sciences.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"There are neither relationships with industry and organizations in this study, nor potential conflicts of interest between authors and other persons.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"214"}}